WO1991005536A3 - Novel oxidized lipoproteins and methods for their preparation - Google Patents

Novel oxidized lipoproteins and methods for their preparation Download PDF

Info

Publication number
WO1991005536A3
WO1991005536A3 PCT/US1990/005679 US9005679W WO9105536A3 WO 1991005536 A3 WO1991005536 A3 WO 1991005536A3 US 9005679 W US9005679 W US 9005679W WO 9105536 A3 WO9105536 A3 WO 9105536A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipoproteins
oxidized
methods
lipoprotein
oxidize
Prior art date
Application number
PCT/US1990/005679
Other languages
French (fr)
Other versions
WO1991005536A2 (en
Inventor
Eric T Fossel
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Priority to BR909007725A priority Critical patent/BR9007725A/en
Publication of WO1991005536A2 publication Critical patent/WO1991005536A2/en
Publication of WO1991005536A3 publication Critical patent/WO1991005536A3/en
Priority to FI921430A priority patent/FI921430A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Lighting Device Outwards From Vehicle And Optical Signal (AREA)

Abstract

Methods and apparatuses are disclosed for preparing novel oxidized lipoprotein compositions. Peroxides are capable of generating free-radicals which, in turn, can oxidize lipoproteins in vitro or in vivo. It has been discovered that hydrogen peroxide itself or in conjunction with certain enzymes such as peroxidase or lipoxidase can oxidize lipoproteins. Peroxidized low density lipoproteins are the most preferred composition. Oxidized lipoproteins exhibit a cytotoxic effect to which diseased cells which are more susceptible than healthy cells. Thus, oxidized lipoproteins may be useful in treating many disease states. The extent of lipoprotein peroxidation is measured by obtaining a C-13 NMR spectrum of the oxidized lipoprotein solution.
PCT/US1990/005679 1989-10-06 1990-10-04 Novel oxidized lipoproteins and methods for their preparation WO1991005536A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR909007725A BR9007725A (en) 1989-10-06 1990-10-04 METHOD FOR THE PREPARATION OF OXIDIZED LIPOPROTEINS, METHOD FOR THE PREPARATION OF LOW DENSITY OXIDATED LIPOPROTEINS, COMPOSITION OF LOW DENSITY OXIDATED LIPOPROTEIN AND APPLIANCE FOR LIPOPROTEIN OXIDATION
FI921430A FI921430A0 (en) 1989-10-06 1992-04-01 OXIDERAD LIPOPROTEIN OCH FOERFARANDE FOER DESS FRAMSTAELLNING.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41838289A 1989-10-06 1989-10-06
US418,382 1989-10-06

Publications (2)

Publication Number Publication Date
WO1991005536A2 WO1991005536A2 (en) 1991-05-02
WO1991005536A3 true WO1991005536A3 (en) 1991-08-08

Family

ID=23657894

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1990/005679 WO1991005536A2 (en) 1989-10-06 1990-10-04 Novel oxidized lipoproteins and methods for their preparation
PCT/US1990/005680 WO1991004744A1 (en) 1989-10-06 1990-10-04 Methods and apparatus for treating disease states using oxidized lipoproteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1990/005680 WO1991004744A1 (en) 1989-10-06 1990-10-04 Methods and apparatus for treating disease states using oxidized lipoproteins

Country Status (7)

Country Link
EP (2) EP0494992A4 (en)
JP (2) JPH05500963A (en)
AU (2) AU7040091A (en)
BR (2) BR9007721A (en)
CA (2) CA2067364A1 (en)
FI (2) FI921430A0 (en)
WO (2) WO1991005536A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674753B1 (en) * 1991-04-02 1995-03-10 Jean Berque NEW THERAPEUTIC INDICATIONS, PARTICULARLY FOR THE TREATMENT OF AIDS, OF AN ALREADY EXISTING MEDICINAL PRODUCT FROM A DENIMOUS MOLECULE OF CONTRAINDICATIONS AND ADVERSE REACTIONS.
WO1994023302A1 (en) * 1993-04-07 1994-10-13 The Australian National University Immunological assay of oxidatively modified human low density lipoproteins in plasma
PT1328289E (en) * 2000-10-20 2008-12-10 Hamburger Stiftung Zur Foerder Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
AU2003232209A1 (en) * 2003-04-25 2004-11-23 Hamburger Stiftung Zur Forderung Von Wissenschaft Und Kultur Treatment of hi-virus infections with oxidised blood proteins
WO2006059082A1 (en) * 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
US10775458B2 (en) 2018-03-05 2020-09-15 Texas Tech University System Method and system for non-invasive measurement of metabolic health

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2095388A (en) * 1935-08-03 1937-10-12 Bendix Radio Corp Electrical regulator apparatus
US2095338A (en) * 1927-08-20 1937-10-12 Ig Farbenindustrie Ag Process for oxidizing organic substances in the liquid phase and apparatus therefor
US3655700A (en) * 1970-02-02 1972-04-11 Zoecon Corp Oxygenated unsaturated aliphatic carboxylic acids and esters
US4226713A (en) * 1978-04-24 1980-10-07 Goldberg Jack M Diagnostic agents
US4472303A (en) * 1981-07-10 1984-09-18 Kuraray Co., Ltd. Blood purification method
DD243714A1 (en) * 1985-10-08 1987-03-11 Akad Wissenschaften Ddr PROCESS FOR STABILIZING IMMOBILIZED GLUCOSE OXIDASE

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2095338A (en) * 1927-08-20 1937-10-12 Ig Farbenindustrie Ag Process for oxidizing organic substances in the liquid phase and apparatus therefor
US2095388A (en) * 1935-08-03 1937-10-12 Bendix Radio Corp Electrical regulator apparatus
US3655700A (en) * 1970-02-02 1972-04-11 Zoecon Corp Oxygenated unsaturated aliphatic carboxylic acids and esters
US4226713A (en) * 1978-04-24 1980-10-07 Goldberg Jack M Diagnostic agents
US4472303A (en) * 1981-07-10 1984-09-18 Kuraray Co., Ltd. Blood purification method
DD243714A1 (en) * 1985-10-08 1987-03-11 Akad Wissenschaften Ddr PROCESS FOR STABILIZING IMMOBILIZED GLUCOSE OXIDASE

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DIXON et al Enzymes (1979 Academic Prss, New York) p. 740-741, enzymes 1.11.1.3 and 1.11.1.7. *
GARNER, CHEMICAL ABSTRACTS 1-12 Volum 102, 1985 Abstract 42042 39. *
GARNER, CHEMICAL ABSTRACTS, Vol. 102, 1985 Abstract 42042. *
LUTHER, et al 12 October 1937 (Entire document). *
POKORNY et al CHEMICAL ABSTRACTS, Vol. 78, 1973 Abstract 39713V. *
See also references of EP0495014A4 *
Wako Pure Chemical, CHEMICAL ABSTRACTS Vol. 95, 1981, Abstract 128864p. *
Wako Pure Chemicals. CHEMICAL ABSTRACTS, Vol. 95, 1981 Abstract 128864P. *
YOSHIOKA et al, CHEMICAL ABSTRACTS Vol. 97, 1982 Abstract 160247. *
YOSHIOTIA, et al CHEMICAL ABSTRACTS Vol. 97, 1982 Abstract 160240j. *

Also Published As

Publication number Publication date
CA2067356A1 (en) 1991-04-07
FI921431A0 (en) 1992-04-01
FI921431A (en) 1992-04-01
FI921430A (en) 1992-04-01
JPH05500963A (en) 1993-02-25
WO1991005536A2 (en) 1991-05-02
AU7045291A (en) 1991-05-16
FI921430A0 (en) 1992-04-01
AU7040091A (en) 1991-04-28
WO1991004744A1 (en) 1991-04-18
CA2067364A1 (en) 1991-04-07
BR9007721A (en) 1992-08-18
BR9007725A (en) 1992-08-18
EP0494992A1 (en) 1992-07-22
EP0495014A1 (en) 1992-07-22
EP0494992A4 (en) 1993-03-31
JPH05501258A (en) 1993-03-11
EP0495014A4 (en) 1993-07-28

Similar Documents

Publication Publication Date Title
BR0116376B1 (en) perfume composition, consumer product, tissue treatment, personal care, hard surface treatment and air treatment compositions, and non-therapeutic method to provide positive mood benefits, particularly relaxation benefits, to an individual .
CA2395674A1 (en) Methods and compositions for reconstruction of multilayered tissue structures
CA2286655A1 (en) Tissue decellularization
ES2182869T3 (en) SACARIDO NO REDUCTOR AND ITS USE.
MXPA01008125A (en) Composition for the oxidation dyeing of keratinous fibers comprising at least one oxidation dye and at least one cationic amphiphilic polymer, and dyeing methods.
EP2277992A3 (en) Progenitor cells from Wharton's jelly of human umbilical cord
GB2331015A (en) Therapeutic methods and compositions involving isoflavones
BRPI0413241A (en) monatin table sweetener compositions and methods of making the same
CA2053258A1 (en) Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorption
NZ229212A (en) Heparin derivatives and preparation
MXPA03011176A (en) Pseudoplastic, film forming cosmetic compositions.
WO1991005536A3 (en) Novel oxidized lipoproteins and methods for their preparation
CA2099356A1 (en) Hydroxylated Milk Glycerides
DE59913103D1 (en) SUBSTITUTED 4-AMINO-2-ARYL-CYCLOPENTA ÄDÜPYRIMIDINE, THEIR PREPARATION, THEIR USE AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
EP0824910A3 (en) Use of a Krill Enzyme for the Treatment of Dental Plaque
EP0117070A3 (en) Cosmetic sticks
FR2792831A1 (en) COMPOSITION FOR COSMETIC AND / OR DIETETIC USE COMPRISING A MIXTURE OF LYCOPENE AND OLIVE LEAF EXTRACT
JPS6438007A (en) Skin external preparation
GB8704904D0 (en) Composition
ES2116496T3 (en) PROCESS FOR THE PREPARATION OF 1,4-DISUBSTITUTED-5 (4H) -TETRAZOLINONES.
CA2332532A1 (en) Biomaterials containing hyaluronic acid derivatives in the form of three-dimensional structures free from cellular components or products thereof for the in vivo regeneration of tissue cells
SE8800176L (en) ANTI-INFLAMMATORALLY OXIDATING AGENTS, PROCEDURES FOR PREPARING THEREOF, AND APPLICATION THEREOF
AU3155701A (en) Method and compositions for producing cell transplants
CA2073453A1 (en) Methods of enhancing wound healing and tissue repair
ATE204766T1 (en) SYNTHETIC TRIGLYCERIDE FEELING FOR SURGICALLY IMPLANTED PROSTHESES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA FI JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA FI JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WR Later publication of a revised version of an international search report
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 921430

Country of ref document: FI

WWE Wipo information: entry into national phase

Ref document number: 2067364

Country of ref document: CA

Ref document number: 1991901910

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991901910

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991901910

Country of ref document: EP